- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Alternative Capital and Credit Funds
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Equity
- Real Estate
- Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Insurance Coverage and Recovery
- Intellectual Property, Patent, Trademark and Copyright Litigation
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- Careers
- News & Insights
- About
- Languages
D. Kyle Sampson
News 1 results
Press Release
April 1, 2016
King & Spalding Boosts FDA & Life Sciences Practice with Addition of Three-Lawyer Team in Washington, D.C.
Events 10 results
Webinar
November 21, 2019
FDA’s Regulation of Cannabis: What You Should Know
Conference
November 12, 2019
12th Annual King & Spalding Pharmaceutical University
Webinar
September 12, 2019
Open Borders for Rx Drugs? The Trump Administration’s Move to Authorize Prescription Drug Importation
Conference
November 13, 2018
11th Annual King & Spalding Pharmaceutical University
Insights 16 results
Client Alert
April 30, 2020
Congress Enacts OTC Monograph Reform
Client Alert
March 10, 2020
FDA Releases Progress Report Regarding Enforcement Discretion Policy on Hemp-Derived Cannabidiol (CBD)
Client Alert
January 16, 2020
Congress Holds Hearing on Current & Future Federal Cannabis Policies
Article · Source: Law360
January 16, 2020
HHS Drug Import Proposal Is Unlikely To Succeed